Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant docetaxel versus anthracycline sequence trial in locally advanced breast cancer
ACTRN12605000588695Phase 3Completed
- Sponsor
- Monash Health
- Start
- Jun 2004
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel, epirubicin, fluorouracil, cyclophosphamide and trastuzumab in breast cancer (2 arms), sponsored by Monash Health. Primary endpoint: Identification of markers that correlate with tumour response to chemotherapy. Started Jun 2004; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12605000588695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000588695.